Clearside Biomedical, Inc. (NASDAQ:CLSD) Given Average Rating of “Buy” by Brokerages

Shares of Clearside Biomedical, Inc. (NASDAQ:CLSD) have been assigned an average recommendation of “Buy” from the five analysts that are covering the stock, MarketBeat Ratings reports. Five equities research analysts have rated the stock with a buy recommendation. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $4.60.

CLSD has been the topic of a number of research reports. StockNews.com lowered shares of Clearside Biomedical from a “hold” rating to a “sell” rating in a research report on Friday, May 10th. HC Wainwright reaffirmed a “buy” rating and issued a $5.00 target price on shares of Clearside Biomedical in a report on Tuesday, August 13th. Needham & Company LLC reiterated a “buy” rating and set a $4.00 target price on shares of Clearside Biomedical in a research note on Tuesday, August 13th. Finally, Oppenheimer started coverage on Clearside Biomedical in a research report on Tuesday, June 25th. They issued an “outperform” rating and a $5.00 price target on the stock.

Institutional Trading of Clearside Biomedical

Hedge funds and other institutional investors have recently made changes to their positions in the company. SG Americas Securities LLC acquired a new stake in Clearside Biomedical in the first quarter valued at about $49,000. International Assets Investment Management LLC acquired a new stake in shares of Clearside Biomedical in the 1st quarter valued at approximately $57,000. XTX Topco Ltd boosted its stake in shares of Clearside Biomedical by 172.2% in the second quarter. XTX Topco Ltd now owns 54,313 shares of the company’s stock valued at $71,000 after buying an additional 34,359 shares in the last quarter. Assenagon Asset Management S.A. acquired a new position in Clearside Biomedical during the second quarter worth $368,000. Finally, Renaissance Technologies LLC raised its position in Clearside Biomedical by 6.6% in the second quarter. Renaissance Technologies LLC now owns 582,689 shares of the company’s stock worth $757,000 after acquiring an additional 35,900 shares in the last quarter. Hedge funds and other institutional investors own 18.75% of the company’s stock.

Clearside Biomedical Stock Down 2.0 %

CLSD stock opened at $1.00 on Wednesday. The stock has a market cap of $74.73 million, a price-to-earnings ratio of -1.82 and a beta of 2.43. Clearside Biomedical has a fifty-two week low of $0.65 and a fifty-two week high of $2.12. The business has a 50 day moving average price of $1.16 and a 200 day moving average price of $1.31.

Clearside Biomedical (NASDAQ:CLSD) last announced its earnings results on Monday, August 12th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.04. The firm had revenue of $0.09 million during the quarter, compared to analyst estimates of $0.25 million. During the same period last year, the company earned ($0.15) earnings per share. As a group, sell-side analysts anticipate that Clearside Biomedical will post -0.6 EPS for the current year.

About Clearside Biomedical

Clearside Biomedical, Inc, a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD.